Becton, Dickinson and Company (NYSE:BDX) insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the sale, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Becton, Dickinson and Company (NYSE BDX) traded up 1.33% during midday trading on Friday, reaching $200.86. 510,634 shares of the company’s stock traded hands. The firm’s 50-day moving average is $198.75 and its 200 day moving average is $187.49. The firm has a market cap of $45.71 billion, a PE ratio of 58.17 and a beta of 1.05. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.35 earnings per share. Equities research analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be issued a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.47%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.watchlistnews.com/becton-dickinson-and-company-nysebdx-insider-sells-1839983-43-in-stock/1472765.html.

Hedge funds and other institutional investors have recently modified their holdings of the company. North Star Investment Management Corp. boosted its position in shares of Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 18 shares during the period. Crestwood Advisors Group LLC purchased a new position in shares of Becton, Dickinson and during the first quarter valued at about $101,000. Almanack Investment Partners LLC. purchased a new position in shares of Becton, Dickinson and during the first quarter valued at about $105,000. Parkside Financial Bank & Trust boosted its position in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares during the period. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after buying an additional 240 shares during the last quarter. 75.71% of the stock is owned by institutional investors and hedge funds.

A number of research firms recently weighed in on BDX. BidaskClub lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Sunday, August 6th. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday. Zacks Investment Research lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Monday. Barclays PLC restated an “equal weight” rating and issued a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday. Finally, Cowen and Company restated an “outperform” rating and issued a $230.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $195.79.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Insider Buying and Selling by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.